A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus

Abstract

A critical review of cost-effectiveness analyses of HPv vaccination in males was conducted and nine studies were identified in different countries. Due to the heterogeneity among these studies in terms of modeling approach, vaccination strategies, health outcomes considered, assumptions and parameters, limited conclusions can be drawn with regard to the absolute cost-effectiveness. Nevertheless, key drivers were identified. More favorable cost-effectiveness appeared when all HPv-related diseases outcomes were considered, a suboptimal vaccine coverage among girls and/or lower vaccine prices were assumed. There was a general lack of transparency to fully describe the details of the methodological approach of modeling and calibration. Further research should be conducted to generate robust evidence-based data sets (HPv-related diseases epidemiology, costs and quality of life). The best modeling practice for HPv vaccination and how to better capture the true economic value of vaccination beyond cost-effectiveness in a broader policy context need to be investigated. © 2013 Landes Bioscience.